A Phase IIb, Randomized, Multi-Center, Multinational, Prospective, Double-Blind, Placebo-Controlled Study, With an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in Subjects With ALS
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Celecoxib/ciprofloxacin (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PARADIGM
- Sponsors NeuroSense Therapeutics
- 01 Aug 2024 Results showing 12-month data evaluating the safety and efficacy of PrimeC in people living with Amyotrophic Lateral Sclerosis (ALS) published in the Media Release
- 09 Jul 2024 According to a NeuroSense Therapeutics Media Release,NeuroSense intends to submit 12-month results to regulatory agencies, including the FDA, to discuss PrimeCs path forward in the short term.
- 09 Jul 2024 Results from 12-month PARADIGM Phase 2b study of PrimeC in ALS patients published in the NeuroSense Therapeutics Media Release